- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3%…
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder…
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of…
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced…
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates…
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed…
Plenary presentation of data showing primary efficacy endpoint met – significant analgesia across all dosesSignificant improvement in all signs and…
Moderated Interactive Poster Session to Feature AEROLITH RCT Data on Acoustic Enhancer Microbubble Cavitation with Ureteroscopic Laser Lithotripsy SAN FRANCISCO--(BUSINESS…
Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery BOSTON and…